Alessia Montagnoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alessia Montagnoli has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Jürgen Moll
Nerviano Medical Sciences S.r.l., Via Pasteur 10, Nerviano 20014, Italy
2 shared publications- Alan Jacobsen
Centre for Chromosome Biology, School of Natural Sciences National University of Ireland Galway, Galway, Ireland
1 shared publication - Alessandro Natoni
Apoptosis Research Center, National University of Ireland, Galway, Ireland
1 shared publication - Corrado Santocanale
Centre for Chromosome Biology, School of Biological and Chemical Sciences, University of Galway, Galway, Ireland
1 shared publication - Francesco Colotta
Dompé s.p.a., L'Aquila, Italy
1 shared publication - Gemma O'Brien
Centre for Chromosome Biology, School of Natural Sciences National University of Ireland Galway, Galway, Ireland
1 shared publication
Latest Publications
- Open Access
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models
Two key features of myeloma cells are the deregulation of the cell cycle and the dependency on the expression of the BCL2 family of anti-apoptotic proteins. The cell division cycle 7 (CDC7) is an essential S-phase kinase and emerging CDC7 inhibitors are effective in a variety of preclinical cancer models. These compounds also inhibit CDK9 which is relevant for MCL-1 expression. The activity and mechanism of action of the dual CDC7/CDK9 inhibitor PHA-767491 was assessed in a panel of multiple myeloma cell lines, in primary samples from patients, in the presence of stromal cells and in combination with drugs used in current chemotherapeutic regimens. We report that in all conditions myeloma cells undergo cell death upon PHA-767491 treatment and we report an overall additive effect with melphalan, bortezomib and doxorubicin, thus supporting further assessment of targeting CDC7 and CDK9 in multiple myeloma.
Open AccessCharacterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models
Two key features of myeloma cells are the deregulation of the cell cycle and the dependency on the expression of the BCL2 family of anti-apoptotic proteins. The cell division cycle 7 (CDC7) is an essential S-phase kinase and emerging CDC7 inhibitors are effective in a variety of preclinical cancer models. These compounds also inhibit CDK9 which is relevant for MCL-1 expression. The activity and mechanism of action of the dual CDC7/CDK9 inhibitor PHA-767491 was assessed in a panel of multiple myeloma cell lines, in primary samples from patients, in the presence of stromal cells and in combination with drugs used in current chemotherapeutic regimens. We report that in all conditions myeloma cells undergo cell death upon PHA-767491 treatment and we report an overall additive effect with melphalan, bortezomib and doxorubicin, thus supporting further assessment of targeting CDC7 and CDK9 in multiple myeloma.
- 14 September 2010
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (18) , 4503-4508
Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy
The cell division cycle 7 (Cdc7) is a serine-threonine kinase, originally discovered in budding yeast, required to initiate DNA replication. Human Cdc7 phosphorylates the minichromosome maintenance protein 2 (Mcm2), a component of the DNA replicative helicase needed for genome duplication. Inhibition of Cdc7 in cancer cells impairs progression through S phase, inducing a p53-independent apoptotic cell death, whereas in normal cells, it does not affect cell viability. Small molecule compounds able to interfere with Cdc7 activity have been identified and shown to be effective in controlling tumor growth in animal models. Two Cdc7 inhibitors are currently in phase I clinical development. Inhibition of Cdc7 kinase activity in cancer cells restricts DNA replication and induces apoptotic cell death by an unprecedented molecular mechanism of action. Clin Cancer Res; 16(18); 4503–8. ©2010 AACR.
- 14 September 2010
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (18) , 4503-4508
Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy
The cell division cycle 7 (Cdc7) is a serine-threonine kinase, originally discovered in budding yeast, required to initiate DNA replication. Human Cdc7 phosphorylates the minichromosome maintenance protein 2 (Mcm2), a component of the DNA replicative helicase needed for genome duplication. Inhibition of Cdc7 in cancer cells impairs progression through S phase, inducing a p53-independent apoptotic cell death, whereas in normal cells, it does not affect cell viability. Small molecule compounds able to interfere with Cdc7 activity have been identified and shown to be effective in controlling tumor growth in animal models. Two Cdc7 inhibitors are currently in phase I clinical development. Inhibition of Cdc7 kinase activity in cancer cells restricts DNA replication and induces apoptotic cell death by an unprecedented molecular mechanism of action. Clin Cancer Res; 16(18); 4503–8. ©2010 AACR.